Ossur hf ( (OSSFF) ) has released its Q1 earnings. Here is a breakdown of the information Ossur hf presented to its investors.
Embla Medical hf, a leading company in the medical technology sector, specializes in the development and manufacturing of innovative prosthetics and orthotics. The company operates globally, with a strong presence in the EMEA and APAC regions.
Embla Medical hf reported a solid performance in Q1 2025, with sales reaching USD 203 million, marking a 4% organic growth. The Prosthetics & Neuro Orthotics segment was a significant contributor to this growth, particularly in the EMEA and APAC regions, while the Americas experienced a softer start to the year.
Key financial highlights include a 9% organic growth in the Prosthetics & Neuro Orthotics segment and a gross profit margin increase to 63%, driven by manufacturing cost reductions and a favorable product mix. The EBITDA margin improved to 18%, and net profit rose by 45% to USD 12 million, reflecting strong operational performance and effective cost control measures.
The company remains optimistic about its growth prospects, maintaining its guidance for 5-8% organic sales growth and a 20-21% EBITDA margin for the full year. Embla Medical plans to leverage its recent product launches and the US Medicare coverage expansion to drive future growth.
Looking ahead, Embla Medical is poised to continue its growth trajectory, supported by strategic initiatives and a robust product pipeline. The management remains committed to enhancing shareholder value through disciplined capital allocation and operational excellence.